HMGB1 (High Mobility Group Box 1) antagonistic polypeptide as well as derivative and application thereof

By developing antagonistic polypeptides and their derivatives that specifically bind HMGB1 with high affinity, blocking the HMGB1 signaling pathway, solving the problem of difficult-to-control proliferation and invasion of colorectal cancer cells, and achieving targeted therapeutic effects on colorectal cancer.

CN118930614APending Publication Date: 2024-11-12TSINGHUA SHENZHEN INTERNATIONAL GRADUATE SCHOOL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410908785.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-08
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The prior art has not been able to effectively block the HMGB1 signaling pathway in the treatment of colorectal cancer, resulting in difficult control of tumor cell proliferation and invasion, and limited targeted treatment methods.

Method used

An antagonistic polypeptide and its derivatives specifically with high affinity binding to HMGB1 are developed to inhibit colorectal cancer cell proliferation and promote apoptosis by blocking the HMGB1 signaling pathway, and are used for targeted therapy.

Benefits of technology

It significantly inhibits the proliferation and migration of colorectal cancer cells, provides new targeted treatment methods, and has great application value in preventing and treating colorectal cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930614A_ABST
    Figure CN118930614A_ABST
Patent Text Reader

Abstract

The invention relates to an HMGB1 (High Mobility Group Box 1) antagonistic polypeptide as well as a derivative and application thereof, and particularly discloses the HMGB1 antagonistic polypeptide. The amino acid sequence of the HMGB1 antagonistic polypeptide is shown as SEQ ID No: 1. The antagonistic polypeptide and the derivative thereof can be combined with HMGB1, and can be combined with HMGB1 to block a downstream signal channel so as to inhibit the proliferation of colorectal cancer cells and the invasion and migration of the colorectal cancer cells, so that an effective small molecule medicine for treating colorectal cancer and the like is provided, and the antagonistic polypeptide and the derivative thereof can be widely applied to the fields of medicine and biology.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biotechnology and biomedicine, and specifically relates to an HMGB1 antagonistic polypeptide and its derivatives and applications. Background Art

[0002] Colorectal cancer is a malignant tumor that occurs in the colon and rectum. It is one of the most common cancers in the world, especially in Western countries. Its incidence and mortality rates are increasing year by year. According to global cancer statistics, colorectal cancer has become the third most common cancer in the world. In China, colorectal cancer is also one of the most common cancers. As of 2022, it has become the second most common type of cancer in China, and its mortality rate ranks fourth. The incidence of colorectal cancer shows an upward trend with age, and the overall incidence and mortality rate also show an upward trend. Dietary habits and lifestyle are important risk factors for colorectal cancer. A high-fat, low-fiber Western diet and the intake of red meat and processed meat increase the risk of colorectal cancer. In addition, factors such as genetic factors, inflammatory bowel disease and environmental pollution may also affect the incidence of colorectal cancer.

[0003] The development of colorectal cancer involves abnormal expression and mutation of multiple genes. At the molecular biology level, key gene abnormalities include APC, KRAS and TP53, which play an important role in the onset and progression of colorectal cancer. APC gene mutation is an early event in the development of colorectal adenoma, activating mutations of the KRAS gene lead to persistent activation of cell proliferation and survival signals, and defects in the TP53 gene are associated with the deterioration and poor prognosis of colorectal cancer. In addition, other genes such as BRAF, PIK3CA, SMAD4, etc. have also been found to have mutations in colorectal cancer. Genetic factors play an important role in the onset of colorectal cancer. Familial adenomatous polyposis (FAP) and hereditary non-polyposis colorectal cancer (HNPCC) are genetic gene mutation diseases that cause colorectal cancer. In addition, factors such as inflammatory bowel disease and environmental pollution may also increase the risk of colorectal cancer.

[0004] The strategies for treating colorectal cancer are usually comprehensive. Surgical resection is the main treatment for early colorectal cancer. For advanced or metastatic colorectal cancer, chemotherapy, radiotherapy and targeted therapy are widely used. Chemotherapy uses anticancer drugs, while radiotherapy controls tumor growth by destroying the DNA of cancer cells through radiation. Targeted therapy is a treatment strategy that targets tumor-specific markers or signaling pathways to block the blood supply and growth signals of the tumor. Early screening programs such as colonoscopy and fecal occult blood tests can help detect colorectal cancer and adenoma early and improve patients' survival rate and prognosis. Personalized treatment and immunotherapy are current research hotspots and provide new directions for finding more effective treatments. With the comprehensive use of these treatments, the survival rate and treatment effect of colorectal cancer patients have been significantly improved, but further research and exploration are still needed in prevention and treatment. Summary of the invention

[0005] In order to overcome the deficiencies and shortcomings of the prior art, the primary purpose of the present invention is to provide an HMGB1 antagonist polypeptide, which has a specific high affinity to the receptor HMGB1 and can block the signaling pathway of HMGB1 by binding to HMGB1, proving that the polypeptide plays an important role in targeted inhibition of colorectal cancer cell proliferation, promotion of colorectal cancer cell apoptosis, etc., and has great application value in the targeted treatment of colorectal cancer.

[0006] Another object of the present invention is to provide a derivative of the above HMGB1 receptor antagonist polypeptide, which derivative can also have a specific high affinity with the HMGB1 receptor and specifically bind to HMGB1.

[0007] Another object of the present invention is to provide applications of the above-mentioned HMGB1 antagonist polypeptide and its derivatives.

[0008] In order to achieve the above tasks, the present invention adopts the following technical solutions:

[0009] In one aspect, the present invention provides an HMGB1 antagonist polypeptide, wherein the amino acid sequence is shown in SEQ ID No: 1.

[0010] Another aspect of the present invention provides a derivative of an HMGB1 antagonist polypeptide, wherein the derivative of the HMGB1 antagonist polypeptide is a product obtained by conventionally modifying the amino acid side chain groups of the above-mentioned HMGB1 antagonist polypeptide, the amino terminus or the carboxyl terminus of the above-mentioned HMGB1 antagonist polypeptide fragment, or is a product obtained by connecting the above-mentioned HMGB1 antagonist polypeptide to a tag for polypeptide or protein detection or purification; the conventional modification is amination, amidation, hydroxylation, carboxylation, carbonylation, alkylation, acetylation, phosphorylation, esterification, glycosylation, cyclization, biotinylation, fluorescent group modification, polyethylene glycol PEG modification or immobilization modification, etc.; the tag is His6, GST, EGFP, MBP, Nus, HA, IgG, FLAG, c-Myc or ProfinityeXact, etc.

[0011] The HMGB1 antagonist polypeptide derivative is preferably: the terminal of the HMGB1 antagonist polypeptide is amidated.

[0012] The HMGB1 antagonist polypeptide and its derivatives can be derived from mammals or birds, such as primates (humans); rodents, including mice, rats, hamsters, rabbits, horses, cattle, dogs, cats, etc.

[0013] The HMGB1 antagonist polypeptide and its derivatives are obtained by using the known methods in the prior art, such as chemical synthesis using an automatic polypeptide synthesizer; deducing the nucleotide sequence from the short peptide sequence and then cloning it into a vector for biosynthesis; or extracting and purifying in large quantities from existing organisms.

[0014] In another aspect, the present invention provides a polynucleotide encoding the above-mentioned HMGB1 antagonist polypeptide or a derivative of the above-mentioned HMGB1 antagonist polypeptide.

[0015] In yet another aspect, the present invention provides a vector comprising the above-mentioned polynucleotide, which can be linked to a promoter sequence by means of genetic technology.

[0016] Another aspect of the present invention provides a host cell transfected with the above-mentioned vector.

[0017] In another aspect, the present invention provides a pharmaceutical composition, which comprises the above-mentioned HMGB1 antagonist polypeptide or the above-mentioned HMGB1 antagonist polypeptide derivative; one or more combinations of the above-mentioned polynucleotide, the above-mentioned vector and the above-mentioned host cell.

[0018] In the technical solution of the present invention, the pharmaceutical composition contains one or more pharmaceutically acceptable carriers;

[0019] In the technical solution of the present invention, the pharmaceutically acceptable carrier is preferably a diluent, an excipient, a filler, a binder, a wetting agent, a disintegrant, an absorption promoter, an adsorption carrier, a surfactant or a lubricant, etc.;

[0020] In the technical solution of the present invention, the pharmaceutical composition can be further prepared into various forms such as tablets, granules, capsules, oral liquids or injections, and the drugs in various dosage forms can be prepared according to conventional methods in the pharmaceutical field.

[0021] In yet another aspect, the present invention provides a detection reagent, which comprises the above-mentioned HMGB1 antagonist polypeptide or a derivative of the above-mentioned HMGB1 antagonist polypeptide.

[0022] In another aspect, the present invention provides antibodies against the above-mentioned HMGB1 antagonist polypeptide or its derivatives.

[0023] In another aspect, the present invention provides use of the HMGB1 antagonist polypeptide and the derivative of the HMGB1 antagonist polypeptide of the present invention in the preparation of a drug for inhibiting the proliferation of tumor cells that highly express HMGB1.

[0024] In another aspect, the present invention provides use of the HMGB1 antagonist polypeptide and the derivative of the HMGB1 antagonist polypeptide of the present invention in the preparation of a drug for promoting apoptosis of tumor cells that highly express HMGB1.

[0025] In the technical solution of the present invention, the tumor cells that highly express HMGB1 are selected from rectal cancer cells and colon cancer cells.

[0026] In another aspect, the present invention provides use of the HMGB1 antagonist polypeptide and the HMGB1 antagonist polypeptide derivatives of the present invention in the preparation of a drug for treating tumor diseases with high expression of HMGB1.

[0027] In the technical solution of the present invention, the tumor disease with high expression of HMGB1 is selected from rectal cancer, colon cancer, breast cancer, bile duct cancer, glioma, endometrial cancer, lung cancer, and gastric adenocarcinoma.

[0028] In further experiments, the function of HMGB1 antagonist peptide was verified using colorectal cancer cells HCT-116 that highly expressed HMGB1 as a cell model. Compared with the control group, it was found that HL12-CP1 could significantly inhibit the proliferation of colorectal cancer cells HCT-116.

[0029] In another specific experiment of the present invention, clone formation, scratch and other experiments were used to find that the HMGB1 antagonist polypeptide inhibited the migration and invasion of HCT116 cells.

[0030] Compared with the prior art, the present invention has at least the following beneficial effects:

[0031] (1) The present invention provides an HMGB1 antagonist polypeptide and its derivatives, wherein the antagonist polypeptide and its derivatives can specifically bind to HMGB1 and specifically bind to HMGB1 to inhibit the HMGB1 signaling pathway.

[0032] (2) The HMGB1 antagonist polypeptides and their derivatives screened by the present invention can inhibit the proliferation of colorectal cancer cells and promote apoptosis of colorectal cancer cells by blocking the signaling pathway of HMGB1, and can be used as biological polypeptide drugs of HMGB1 binding sites, and can be used to prepare drugs for preventing and / or treating colorectal cancer. They can be widely used in the fields of medicine and biology, and generate huge social and economic benefits. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Figure 1 This is a diagram showing the hydrophilicity test results of the HMGB1 antagonist polypeptide HM1 of the present invention;

[0034] Figure 2 The results of the binding ability of HM1 to HMGB1 in HCT116 cells in Example 1 of the present invention are shown in Figure A; wherein the blue in Figure A is the cell nucleus, the green in Figure A is HM1-FITC, the red in Figure A is the HMGB1 antibody, and the merged graph; the blue in Figure B is the cell nucleus, the green in Figure A is HM1-FITC, the red in Figure A is the HMGB1 antibody, and the merged graph;

[0035] Figure 3 The results of the HM1 inhibiting the proliferation of colorectal cancer cells HCT116 in Example 2 of the present invention are shown in Figure A; Figure A is a detection diagram of the clone formation ability of HCT116 cells in Example 2 of the present invention, and Figure B is a quantitative histogram of the clone formation ability of HCT116 cells in Figure A;

[0036] Figure 4 The results of the HM1 inhibiting the migration of colorectal cancer cells HCT116 in Example 3 of the present invention are shown in Figure A; Figure A is a detection diagram of the migration ability of HCT116 cells in Example 3 of the present invention, and Figure B is a quantitative histogram of the migration ability of HCT116 cells in Figure A;

[0037] Figure 5 The figure shows the result of HM1 inhibiting the activity of HCT116 cells. DETAILED DESCRIPTION

[0038] HMGB1 protein is a highly conserved nuclear protein that is widely present in the cell nucleus. Its name comes from "High Mobility Group Box 1". It is a small molecule DNA binding protein that is mainly distributed in the cell nucleus, but can also be released from the cell nucleus to the outside of the cell under conditions such as cell stress or death, and plays an important role in regulating cell signals outside the cell. HMGB1 protein participates in the regulation of DNA and the stability of chromatin structure in the cell nucleus, and plays an important role in the regulation of gene expression. As a transcription factor, it can bind to the irregular structure of DNA and regulate the transcriptional activity of genes. In addition, HMGB1 is also involved in physiological processes such as DNA damage repair, chromatin remodeling, and cell differentiation in the cell nucleus, which is essential for maintaining normal cell function. HMGB1 also plays an important role in pathological processes. Under pathological conditions such as infection, inflammation, and cell damage, HMGB1 can be released from the cell nucleus to the cytoplasm, and then released outside the cell through a cell death process called "apoptosis". In this extracellular state, HMGB1 is called "extracellular HMGB1" and becomes a key regulatory molecule for inflammation and immune response. In colorectal cancer, HMGB1 protein plays an important role. HMGB1 can promote tumor cell proliferation and invasion. Studies have shown that the expression level of HMGB1 is significantly increased in colorectal cancer tissues. HMGB1 activates multiple signaling pathways such as NF-κB (nuclear factor κB) and MAPK (mitochondrial-associated protein kinase) by binding to specific receptors such as RAGE (Advanced Glycation End products Receptor) and TLR4 (Toll-Like Receptor 4), thereby promoting tumor cell proliferation, survival and invasion. High levels of HMGB1 expression have been found in the metastasis and worsening prognosis of colorectal cancer. It can also regulate tumor immune escape, and HMGB1 has a regulatory effect on the immune response of tumors. In colorectal cancer, HMGB1 can affect the attack of immune cells on tumors by regulating the activity of immune cells and cytokine release in the tumor microenvironment. On the one hand, HMGB1 can promote tumor cells to release immunosuppressive factors and inhibit the activity of immune cells, thereby helping tumor cells escape the attack of the immune system. On the other hand, HMGB1 can also induce immune cells to release a variety of inflammatory factors, forming an inflammatory microenvironment of the tumor, further promoting tumor growth and spread. In addition, due to the complex role of HMGB1 in colorectal cancer, it has become a potential therapeutic target. Researchers are exploring ways to inhibit tumor cell proliferation and invasion by inhibiting the activity of HMGB1. Some experimental studies have shown that in vitro and animal models, the development and spread of colorectal cancer can be inhibited by intervening in the expression or function of HMGB1. These studies provide new directions for the targeted therapy of HMGB1 and new possibilities for the personalized treatment of colorectal cancer.

[0039] The inventors found that HMGB1 plays a complex role in colorectal cancer, promoting tumor growth and invasion and possibly regulating tumor immune escape. In-depth research on the regulatory mechanism of HMGB1 in colorectal cancer can provide important clues for finding new treatment strategies and targeted therapies, and bring hope for personalized treatment of colorectal cancer patients.

[0040] Phage display technology is a biotechnology method commonly used for peptide screening. It uses bacteriophage as a carrier to display peptides or protein fragments, and screens peptides or protein fragments that bind to specific targets. Phage display technology has the advantages of high efficiency, high throughput and high sensitivity in peptide screening, and is widely used in drug discovery, protein interaction research, tumor treatment and immunology research. Through this technology, peptides or protein fragments that specifically bind to the target can be screened, providing a powerful tool for disease treatment and biological research.

[0041] In order to understand the present invention more clearly, the present invention is further described with reference to the following examples and drawings. The examples are only used for explanation and are not intended to limit the present invention in any way.

[0042] In the examples, all raw reagents and materials are commercially available, and experimental methods without specific conditions are conventional methods and conditions well known in the art, or are based on the conditions recommended by instrument manufacturers.

[0043] Example 1: Selection, amplification, purification, sequencing and synthesis of HMGB1 antagonist peptide HM1

[0044] The HMGB1 antagonist polypeptide (sample sequence Thr-Val-Leu-Asn-Ser-Gly-Asn-Gln-Thr-Met-Leu-Thr, represented by HM1) used in the following examples was synthesized by Shanghai Qiangyao Biotechnology Co., Ltd. The hydrophilicity of the HM1 sequence was analyzed through the official website of Qiangyao Biotechnology Co., Ltd. Figure 1 The results shown are from Figure 1 It can be seen that the polypeptide has good hydrophilicity and may effectively bind to HMGB1.

[0045] Example 2: HM1 can bind to HMGB1 in HCT116 cells

[0046] HCT116 cells in good condition were inoculated in a 12-well plate containing a crawling slide, and fresh culture medium was added for overnight culture. The next morning, HM1 peptide labeled with FITC was added and cultured for 6 hours. The slides with cells crawled on the culture plate were washed with PBS 3 times, each time for 3 minutes; the crawling slides were fixed with 4% paraformaldehyde for 15 minutes, and the slides were washed with PBS 3 times, each time for 3 minutes; 0.5% Triton X-100 (prepared in PBS) was permeabilized at room temperature for 20 minutes; the slides were washed with PBS 3 times, 3 minutes each time, PBS was absorbed with absorbent paper, and a blocking solution containing 3% BSA was added to the slides, and the slides were blocked at room temperature for 30 minutes; the blocking solution was absorbed with absorbent paper, and no washing was done. A sufficient amount of diluted HMGB1 primary antibody was added to each slide and placed in a wet box, and incubated overnight at 4°C; the fluorescent secondary antibody was added the next day: the slides were washed with PBST 3 times, 3 minutes each time, the excess liquid on the slides was absorbed with absorbent paper, and the diluted fluorescent secondary antibody was added, and the slides were incubated in a wet box at 20-37°C for 1 hour, and the sections were washed with PBST 3 times, 3 minutes each time; nuclear re-staining: DAPI was added and incubated in the dark for 5 minutes, and the specimens were stained with nuclear re-staining, and the excess DAPI was washed with PBST 5 minutes × 4 times; the liquid on the slides was absorbed with absorbent paper, and the slides were sealed with a sealing solution containing an anti-fluorescence quencher, and then the images were collected and observed under a fluorescence microscope. The results are as follows Figure 2 ,It can be seen from the figure that the green FITC-HM1 and the red HMGB1 protein in the experimental group can effectively overlap, confirming that HM1 can effectively bind to HMGB1.

[0047] Example 3: HM1 can inhibit the proliferation of HCT116 cells

[0048] Colorectal cancer cells HCT116 were inoculated at 1000 cells / well in a 6-well cell culture plate, with a medium volume of 2 mL per well, and cultured for 24 hours. Then, 20 μM HM-1 and an appropriate amount of fresh medium were added, and the group without drug addition was used as a control. The medium and drugs were replaced every two days, and the culture was continued until the cell cluster contained more than 50 cells. After the experimental group and the control group cells were fixed with methanol, 0.1% crystal violet staining was performed, and the number of clones formed in each group was counted. The results are shown in FIG. Figure 3 ,As can be seen from the figure, compared with the control group, HM1 can effectively inhibit the number of cell clones and the formation of clones, ,which proves that HM1 can effectively inhibit cell proliferation.

[0049] Example 4: HM1 can inhibit the migration of HCT116 cells

[0050] Cell migration was assessed using a scratch assay. Briefly, a horizontal line was marked on the bottom of each 6-well plate as a reference point for image acquisition. HCT116 cells were seeded into 6-well plates at 3x105 cells per well and cultured to 90% confluence. The cells were scratched with a 200 μL pipette tip to form a cell-free area, and then gently washed three times with PBS to remove the detached cells. The plate was then incubated in an appropriate amount of fresh culture medium containing 20 μM HM-1 for 48 hours and the untreated group was used as a control. The cell-free area was imaged, and the gap distance was quantitatively calculated using ImageJ 1.46r software. The results are shown in Figure 2. Figure 4 Experiments have shown that HM1 can effectively inhibit cell migration.

[0051] Example 5: MTT assay to detect the inhibitory effect of HM1 on HCT116 cells

[0052] HCT116 cells were inoculated in a 10 cm culture dish and cultured with 10% FBS DMEM medium to a density of 80%. When the cells reached the required density, the medium was removed, washed twice with PBS, 1 mL of trypsin was added, and digestion was incubated at 37 degrees for 1 min. Then 1 mL of 10% FBS DMEM medium was added, and the cells were beaten to disperse. 10 μL of the cell suspension was drawn and added to 1 mL of DMEM medium to prepare a cell suspension. The number of cells in the prepared cell suspension was counted with a cell counting plate, and then 5 × 10 cells were added to each well. 3 The cells were inoculated in a 96-well plate and cultured for 24 hours. The next day, the cell culture medium was discarded, and fresh culture medium and different concentrations of HM1 were added to the culture plate. The culture plate was incubated in an incubator for 24 hours. 20 μL of MTT solution was added to each well (be careful not to generate bubbles in the wells, as they will affect the OD value reading). The culture plate was incubated in the incubator for 4 hours, and the absorbance at 490 nm was measured with an enzyme reader. The cell viability was then calculated according to the following formula, and an inhibition curve was drawn. Cell viability (%) = [A(drug added) - A(blank)] / [A(0 drug added) - A(blank)] × 100, A(drug added): OD value of the wells with cells, MTT solution and drug solution, A(0 drug added): OD value of the wells with cells, MTT solution but no drug solution, A(blank): OD value of the wells without cells. Results are shown in Figure 4 .Depend on Figure 4 It can be seen that with the increase of drug concentration, cell viability continued to decrease, and the IC50 value of the cells was about 18.4 μM.

Claims

1. A HMGB1 antagonist polypeptide, Features: The amino acid sequence of the HMGB1 antagonist polypeptide is shown in SEQ ID No:

1.

2. A derivative of an HMGB1 antagonist polypeptide, Features: The derivative of the HMGB1 antagonist polypeptide is a product obtained by conventionally modifying the amino acid side chain groups of the HMGB1 antagonist polypeptide of claim 1 or the amino or carboxyl terminus of the HMGB1 antagonist polypeptide fragment of claim 1, or a product obtained by connecting a tag for polypeptide or protein detection or purification to the HMGB1 antagonist polypeptide of claim 1; The conventional modification is amino, amidation, hydroxylation, carboxylation, carbonylation, alkylation, acetylation, phosphorylation, esterification, glycosylation, cyclization, biotinylation, fluorescent group modification, polyethylene glycol PEG modification or immobilization modification; The tag is His 6 , GST, EGFP, MBP, Nus, HA, IgG, FLAG, c-Myc or ProfinityXact.

3. A polynucleotide, Features: It encodes the HMGB1 antagonist polypeptide according to claim 1 or the derivative of the HMGB1 antagonist polypeptide according to claim 2.

4. A carrier, Features: It comprises the polynucleotide according to claim 3.

5. A host cell, Features: It is transfected with the vector described in claim 4.

6. A pharmaceutical composition, Features: The pharmaceutical composition comprises the HMGB1 antagonist polypeptide of claim 1 or the derivative of the HMGB1 antagonist polypeptide of claim 2; a combination of one or more of the polynucleotide of claim 3, the vector of claim 4, and the host cell of claim 5; Preferably, the pharmaceutical composition contains one or more pharmaceutically acceptable carriers; More preferably, the pharmaceutically acceptable carrier is a diluent, an excipient, a filler, a binder, a wetting agent, a disintegrant, an absorption enhancer, an adsorption carrier, a surfactant or a lubricant.

7. A detection reagent, Features: The detection reagent comprises the HMGB1 antagonist polypeptide according to claim 1 or the derivative of the HMGB1 antagonist polypeptide according to claim 2.

8. An antibody against an HMGB1 antagonist polypeptide or a derivative of an HMGB1 antagonist polypeptide, Features: The HMGB1 antagonist polypeptide is the HMGB1 antagonist polypeptide according to claim 1 , and the HMGB1 antagonist polypeptide derivative is the HMGB1 antagonist polypeptide derivative according to claim 2 .

9. Use of the HMGB1 antagonist polypeptide according to claim 1 or the derivative of the HMGB1 antagonist polypeptide according to claim 2 in the preparation of a drug for inhibiting the proliferation of tumor cells that highly express HMGB1 or promoting the apoptosis of tumor cells that highly express HMGB1; Preferably, the tumor cells highly expressing HMGB1 are selected from rectal cancer cells and colon cancer cells.

10. Use of the HMGB1 antagonist polypeptide according to claim 1 or the derivative of the HMGB1 antagonist polypeptide according to claim 2 in the preparation of a drug for treating tumor diseases with high expression of HMGB1; Preferably, the tumor disease with high expression of HMGB1 is selected from rectal cancer, colon cancer, breast cancer, bile duct cancer, glioma, endometrial cancer, lung cancer, and gastric adenocarcinoma.